Muhimbili National Hospital, Dar Es Salaam, United Republic of Tanzania.
Kilimanjaro Christian Medical Centre, Moshi, United Republic of Tanzania.
Pan Afr Med J. 2021 Jul 28;39(Suppl 1):4. doi: 10.11604/pamj.supp.2021.39.1.21358. eCollection 2021.
intussusception surveillance was initiated in Tanzania in 2013 after monovalent rotavirus vaccine was introduced, as part of the 7-country African evaluation to assess whether the vaccine was associated with an increased risk of intussusception. An increased risk from vaccine was not identified. Published data on intussusception in Tanzanian infants are limited.
prospective intussusception surveillance was conducted at 7 referral hospitals during 2013-2016 to identify all infants with intussusception meeting Brighton Level 1 criteria. Demographic, household and clinical data were collected by hospital clinicians and analyzed.
a total of 207 intussusception cases were identified. The median age of cases was 5.8 months and nearly three-quarters were aged 4-7 months. Median number of days from symptom onset to admission at treatment hospital was 3 (IQR 2-5). Seventy-eight percent (152/195) of cases had been admitted at another hospital before transfer to the treating hospital. Enema reduction was not available; all infants were treated surgically and 55% (114/207) had intestinal resection. The overall case-fatality rate was 30% (62/206). Compared with infants who survived, those who died had longer duration of symptoms before admission to treatment hospital (median 4 vs 3 days; p < 0.01), higher rate of intestinal resection (81% [60/82] vs 44% [64/144], p < 0.001), and from families with lower incomes (i.e., less likely to own a television [p < 0.01] and refrigerator [p < 0.05).
Tanzanian infants who develop intussusception have a high case-fatality rate. Raising the index of suspicion among healthcare providers, allocating resources to allow wider availability of abdominal ultrasound for earlier diagnosis, and training teams in ultrasound-guided enema reduction techniques used in other African countries could reduce the fatality rate.
2013 年,单价轮状病毒疫苗在坦桑尼亚推出后,开始进行肠套叠监测,这是 7 个非洲国家评估的一部分,旨在评估该疫苗是否与肠套叠风险增加有关。未发现疫苗有增加风险。关于坦桑尼亚婴儿肠套叠的已发表数据有限。
2013 年至 2016 年,在 7 家转诊医院进行前瞻性肠套叠监测,以确定符合布莱顿 1 级标准的所有肠套叠婴儿。由医院临床医生收集人口统计学、家庭和临床数据,并进行分析。
共发现 207 例肠套叠病例。病例的中位年龄为 5.8 个月,近 3/4 的年龄为 4-7 个月。从症状发作到治疗医院入院的中位天数为 3 天(IQR 2-5)。78%(152/195)的病例在转至治疗医院前已在另一家医院住院。未提供灌肠复位;所有婴儿均接受手术治疗,55%(114/207)行肠切除术。总病死率为 30%(62/206)。与存活的婴儿相比,死亡的婴儿在入院治疗前症状持续时间更长(中位数 4 天 vs 3 天;p<0.01),肠切除术率更高(81%[60/82] vs 44%[64/144],p<0.001),且来自收入较低的家庭(即,拥有电视的可能性较小[ p<0.01]和冰箱[p<0.05]。
坦桑尼亚发生肠套叠的婴儿病死率较高。提高医疗保健提供者的警惕性,分配资源以允许更广泛地使用腹部超声进行早期诊断,并在其他非洲国家培训团队使用超声引导的灌肠复位技术,可能会降低病死率。